Asthma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Asthma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Asthma therapeutics.

Synopsis

• In 2022, there will be more than 260.6 million diagnosed prevalent cases of Asthma across 16 pharmaceutical markets.
• GSK is a key player in the disease space with four key products for asthma. Other main players include AstraZeneca, with two products, and Boehringer Ingelheim and Roche, with one product each.
• The asthma pipeline consists of 373 pharmaceuticals spanning all stages of development, with approximately 20% of drugs in mid- to late-stage development.
• Commercial sponsors dominate clinical trial development in asthma, with the US emerging as the key country for conducting trials in this disease space.
• In deals involving asthma assets, acquisitions are the most common deal in North America and Europe.
• One innovator product approval and one biosimilar approval are expected within the next 18 months.

Scope

GlobalData’s Asthma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Retail or Manufacturer Price of Products
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Asthma market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Asthma market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.